GSK Announced Results From First-ever Efficacy Trial Of Shingrix (Recombinant Zoster Vaccine Or RZV) In China From Phase IV Trial Of RZV In Preventing Shingles In Almost 6,000 Participants Aged 50 Years And Above, Showing Vaccine Efficacy Was Up To 97%
Portfolio Pulse from Benzinga Newsdesk
GSK has announced the results from the first-ever efficacy trial of Shingrix (Recombinant Zoster Vaccine or RZV) in China. The Phase IV trial, which involved nearly 6,000 participants aged 50 years and above, showed that the vaccine's efficacy was up to 97%.
August 23, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's Shingrix vaccine has shown high efficacy in its first trial in China, which could potentially lead to increased sales and market share in the region.
The high efficacy rate of GSK's Shingrix vaccine in its first trial in China indicates a strong potential for the product in the Chinese market. This could lead to increased sales and market share for GSK, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100